Partnering & Outsourcing Editorial

  1. Tips For Establishing & Maintaining An Effective CRO Partnership 12/22/2020

    Strategic CRO partnerships can accelerate timelines, improve efficiencies, enable access to global footprint, and leverage the continuation of corporate knowledge and domain expertise. However, these relationships require constant nurturing and engagement as well as mutual widespread investment between both parties.

  2. Lilly, Care Access Take COVID Trial Directly To Patients 12/10/2020

    Eli Lilly and Company and Care Access Research have forged a unique partnership to develop and manage a first-of-its kind decentralized, mobile trial to safeguard the health of patients in nursing homes. Lilly and Care Access will take the trial directly to patients. 

  3. From Idea To Patient In 10 Weeks: NeuroRx’s Fast Track Approach 11/19/2020

    Psychiatry is an area that Jonathan Javitt never planned to work in. In fact, he still jokes that he flunked a psychiatry class while in medical school. Unfortunately, life has a way of changing your focus. For Javitt, who is now the co-founder and CEO of NeuroRx, that happened 11 years ago when one of his closest friends approached him to say he was battling depression.

  4. How Has COVID Impacted The Clinical Trial Pipeline? 11/12/2020

    As we come to the end of 2020, the world remains focused on finding a vaccine that is effective at halting the spread of COVID-19. The pandemic is already responsible for the deaths of over 1 million people worldwide. In 2020 it also resulted in the cancelling or delay of numerous non-COVID trials for other important medications. 

  5. What Do Small Sponsors Look For When Choosing A CRO? 10/1/2020

    In August, Industry Standard Research (ISR) released the 2020 edition of its CRO Quality Benchmarking Report – Phase II/III Service Providers: A Look at Small and Emerging Biopharma. For this report ISR took a deeper dive into the landscape of small and emerging biopharma companies. The research should help those companies make better informed CRO selection decisions.

  6. COVID-19’s Impact On The Clinical Trial Ancillary Supplies Industry 9/24/2020

    With restrictions on logistics, and countries implementing new restrictions to address increasing COVID-19 cases, it’s important to understand how to manage clinical trials’ ancillary supplies — like sourcing from the right suppliers, managing distribution to all trial sites, stock management, and response to new regulations.

  7. Different CROs For Different Purposes – One Biotech’s Selection Process 9/2/2020

    Morphogenesis has produced a cancer treatment that is injected directly into a tumor. When it came time to find CRO partners to navigate the clinical trial process, the company conducted thorough searches and selected partners based on their needs in a given situation. 

  8. COVID Pandemic Hastens Search For New Technology And CRO Partner 9/1/2020

    As the COVID-19 pandemic began to rage, Mateon Therapeutics was seeking a tool to assist with preclinical development. The crisis meant many patients were suddenly unable to visit clinics. Almost overnight the search for a preclinical development tool was suddenly a high priority.

  9. How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19 8/11/2020

    Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. In July 2020 the company announced the initiation of the first of two Phase 3 clinical trials. To complete those trials, the company knew it had to grow its internal capabilities. It did so by investing heavily in the expansion of its clinical and manufacturing programs.

  10. The First Controlled Clinical Trial For A CRISPR Enhanced Bacteriophage Therapy 6/29/2020

    Several companies are working on bacteriophage therapies, using natural bacteriophage isolated from the environment. Those treatments use the cell’s machinery to create new virus particles that burst out of the cell, killing it in the process and infecting other cells. Locus Biosciences has demonstrated that the CRISPR-Cas3 mechanism makes crPhage significantly more effective at killing target bacteria than their natural counterparts.